These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 8858971

  • 1. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
    Zernig G, Burke T, Lewis JW, Woods JH.
    J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
    [Abstract] [Full Text] [Related]

  • 2. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP, Hill KP, Jiang Q, Sebastian A, Archer S, Bidlack JM.
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [Abstract] [Full Text] [Related]

  • 3. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
    Burke TF, Woods JH, Lewis JW, Medzihradsky F.
    J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
    [Abstract] [Full Text] [Related]

  • 4. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY, Yang HH, Li S, Adams JU.
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [Abstract] [Full Text] [Related]

  • 5. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
    He L, Lee NM.
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
    [Abstract] [Full Text] [Related]

  • 6. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH, Sumpter TL, Burke TF, Husbands SM, Lewis JW, Woods JH, Traynor JR.
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [Abstract] [Full Text] [Related]

  • 7. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
    Paronis CA, Woods JH.
    Eur J Pharmacol; 1997 Oct 15; 337(1):27-34. PubMed ID: 9389377
    [Abstract] [Full Text] [Related]

  • 8. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM, Qian X, Schiller PW, Szeto HH.
    J Pharmacol Exp Ther; 2003 Dec 15; 307(3):947-54. PubMed ID: 14534366
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
    Zernig G, Butelman ER, Lewis JW, Walker EA, Woods JH.
    J Pharmacol Exp Ther; 1994 Apr 15; 269(1):57-65. PubMed ID: 8169852
    [Abstract] [Full Text] [Related]

  • 12. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
    Hirose N, Murakawa K, Takada K, Oi Y, Suzuki T, Nagase H, Cools AR, Koshikawa N.
    Neuroscience; 2005 Apr 15; 135(1):213-25. PubMed ID: 16111831
    [Abstract] [Full Text] [Related]

  • 13. Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography.
    Morris BJ, Millan MJ, Herz A.
    J Pharmacol Exp Ther; 1988 Nov 15; 247(2):729-36. PubMed ID: 2846828
    [Abstract] [Full Text] [Related]

  • 14. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY, Seyed-Mozaffari A, Archer S, Bidlack JM.
    J Pharmacol Exp Ther; 1996 Nov 15; 279(2):539-47. PubMed ID: 8930155
    [Abstract] [Full Text] [Related]

  • 15. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
    Chan K, Brodsky M, Davis T, Franklin S, Inturrisi CE, Yoburn BC.
    Eur J Pharmacol; 1995 Dec 12; 287(2):135-43. PubMed ID: 8749027
    [Abstract] [Full Text] [Related]

  • 16. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.
    Bilsky EJ, Bernstein RN, Hruby VJ, Rothman RB, Lai J, Porreca F.
    J Pharmacol Exp Ther; 1996 Apr 12; 277(1):491-501. PubMed ID: 8613959
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
    Baumhaker Y, Gafni M, Keren O, Sarne Y.
    Mol Pharmacol; 1993 Aug 12; 44(2):461-7. PubMed ID: 8394999
    [Abstract] [Full Text] [Related]

  • 19. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H, Spaulding A, Leitermann R, Wu HE, Nagase H, Tseng LF.
    J Pharmacol Exp Ther; 2003 Jul 12; 306(1):394-400. PubMed ID: 12721333
    [Abstract] [Full Text] [Related]

  • 20. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).
    Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM.
    J Pharmacol Exp Ther; 1992 Aug 12; 262(2):526-31. PubMed ID: 1380079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.